Palisade Bio, Inc.
PALIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Oppenheimer | $7.00(+214%) | $2.23 | StreetInsider | |
| Jun 30, 2026 | H.C. Wainwright | $2.00(-10%) | $2.23 | StreetInsider | |
| Nov 17, 2023 | Maxim Group | Naz Rahman | $1.50(-83%) | $9.07 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2026 |
| Brookline Capital | maintain | Buy | May 13, 2025 |
| Maxim Group | maintain | Buy | Nov 13, 2024 |
| Maxim Group | maintain | Buy | May 1, 2024 |
| Maxim Group | maintain | Buy | Apr 16, 2024 |
| Maxim Group | upgrade | Hold →Buy | Nov 17, 2023 |
| Ladenburg Thalmann | maintain | Buy | May 16, 2023 |
| Maxim Group | upgrade | Hold →Buy | Mar 30, 2023 |
| Maxim Group | downgrade | Buy →Hold | Aug 19, 2022 |
| Ladenburg Thalmann | maintain | Buy | Feb 2, 2022 |
| Maxim Group | maintain | Buy | Aug 31, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.05 | $-0.05 | $500.0K | $500.0K |
| May 12, 2026 | $-0.05 | $-0.04 | — | — |
| Mar 23, 2026 | $-0.04 | $-0.02 | — | — |
| Nov 10, 2025 | $-0.38 | $-0.32 | — | — |
| Aug 11, 2025 | $-0.58 | $-0.48 | — | — |
| May 12, 2025 | $-0.47 | $-0.84 | — | — |
| Mar 25, 2025 | $-2.39 | $-1.99 | — | — |
| Nov 12, 2024 | $-2.32 | $-3.35 | — | — |
News
I initiate Palisade Bio with a "Buy" rating, driven by its differentiated oral PDE4 inhibitor prodrug PALI-2108 targeting inflammatory bowel diseases. PALI's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027, offering a catalyst. Expansion opportunities include a phase 2a trial in Crohn's disease [Q1 2027 start, Q1 2028 data] and potential in fibrostenotic Crohn's, leveraging proven PDE4 biology.
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability
Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts Microbiome and transcriptomic analyses support the delivery platform and a potential precision medicine approach Denver, CO, Oct.
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
Palisade Bio (NASDAQ: PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor designed as a prodrug that is bioactivated in the terminal ileum
Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic dis…
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn's disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Compa…
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D.
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026.
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027 IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn's disease expected in the second half of 2026 Strong balance sheet expected to supp…